R-BAC regimen good for older mantle cell lymphoma patients
At the recent ASH meeting in San Diego, researchers from Italy presented data supporting the use of a new chemotherapy regimen in patients with previously untreated mantle cell lymphoma (MCL), or in patients with relapsed or refractory mantle cell lymphoma who had previously received one line of immunochemotherapy.
The regimen, R-BAC (rituximab, bendamustine, and cytarabine) was given to MCL patients aged 65 or older over 4-6 28 day cycles. A total of 37 patients were enrolled n the phase II study, the overwhelming majority of them with advanced stage (III or IV) disease. The median age of patients was 71.
Overall response rate (ORR) was 88%, and complete response rate (CRR) was 74%. CRR was higher among the treatment naïve patients. At a median 13 month follow-up, the 1 year progression free survival (PFS) rate was 87% in the treatment naïve patients and 62 in the other arm of the trial.
Researchers concluded that the R-BAC regimen not only has potential in treating patients over the age of 65 with mantle cell lymphoma, it is also well-tolerated.
EMPR.com
More Articles
More Articles
Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...
The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...
Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...
At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...
Site Beginnings
This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...
Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...
The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...
The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...
The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...
According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...
Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...
New research suggests that frontline radioimmunotherapy...
Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...
